Posted by Michael Wonder on 18 Jul 2026
Allergan Aesthetics receives approval for Boey (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
17 July 2026 - Allergan Aesthetics announced the European Commission has approved Boey (trenibotulinumtoxinE) in Europe, for the temporary improvement in the appearance of moderate to severe lines between the eyebrows seen at maximum frown (glabellar lines) in adult patients, when these have an important psychological impact.1
Following completion of the centralized procedure, the European Commission decision applies across all 30 European Economic Area countries.
